ridogrel

Ridogrel is a dual-action small molecule drug that acts as both a thromboxane A2 synthase inhibitor and a thromboxane A2/prostaglandin endoperoxide receptor antagonist. It was developed for the prevention of systemic thromboembolism and as an adjunctive agent to thrombolytic therapy in acute myocardial infarction. By inhibiting the synthesis of thromboxane (a potent vasoconstrictor and promoter of platelet aggregation) and blocking its receptor, ridogrel reduces blood clot formation, accelerates recanalization, and may delay or prevent reocclusion during systemic thrombolysis. Although it is more potent than aspirin in some antiplatelet effects, clinical trials have not demonstrated superiority over aspirin for improving outcomes in acute myocardial infarction patients[1][2][3][4][6].

Other names

RidogrelumRidogrelum [INN-Latin]110140-89-1